97 related articles for article (PubMed ID: 10949545)
41. IL-7 mRNA is not overexpressed in mycosis fungoides and pleomorphic T-cell lymphoma and is likely to be an autocrine growth factor in vivo.
Asadullah K; Haeussler A; Friedrich M; Siegling A; Olaizola-Horn S; Trefzer U; Volk HD; Sterry W
Arch Dermatol Res; 1996 Dec; 289(1):9-13. PubMed ID: 9017129
[TBL] [Abstract][Full Text] [Related]
42. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
43. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
44. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
45. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.
Asadullah K; Haeussler-Quade A; Gellrich S; Hanneken S; Hansen-Hagge TE; Döcke WD; Volk HD; Sterry W
Exp Dermatol; 2000 Aug; 9(4):248-51. PubMed ID: 10949545
[TBL] [Abstract][Full Text] [Related]
46. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
48. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
49. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
50. New perspectives in experimental and clinical research for cutaneous T cell lymphomas.
Burg G; Häffner A; Böni R; Dommann S; Dummer R
Recent Results Cancer Res; 1995; 139():225-37. PubMed ID: 7597294
[TBL] [Abstract][Full Text] [Related]
51. Is there a role for epigenetic factors in the pathogenesis of epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome)?
Bachelez H
Hematol J; 2001; 2(4):286-9. PubMed ID: 11920262
[No Abstract] [Full Text] [Related]
52. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
[TBL] [Abstract][Full Text] [Related]
53. Cytokines and cutaneous T-cell lymphomas.
Asadullah K; Döcke WD; Volk HD; Sterry W
Exp Dermatol; 1998 Dec; 7(6):314-20. PubMed ID: 9858133
[TBL] [Abstract][Full Text] [Related]
54. The pathology of cutaneous T-cell lymphoma.
Robson A
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):9-12. PubMed ID: 17474353
[TBL] [Abstract][Full Text] [Related]
55. miRNA in mycosis fungoides and skin inflammation.
Persson JL
APMIS; 2013 Nov; 121(11):1017-9. PubMed ID: 24106870
[TBL] [Abstract][Full Text] [Related]
56. Two cases of syringotropic cutaneous T-cell lymphoma and review of the literature.
Yost JM; Do TT; Kovalszki K; Su L; Anderson TF; Gudjonsson JE
J Am Acad Dermatol; 2009 Jul; 61(1):133-8. PubMed ID: 19539851
[TBL] [Abstract][Full Text] [Related]
57. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
58. [Rare variants of cutaneous T-cell lymphomas].
Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
[TBL] [Abstract][Full Text] [Related]
59. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
